Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Laboratories is supported by a diversified portfolio that is already delivering strong operating momentum, with 2Q revenue of $12.59B, comparable sales up 4.8%, and adjusted EPS of $1.31 beating estimates while gross and operating margins of 58.0% and 22.6% also exceeded expectations. The outlook is constructive because management expects 3Q26 adjusted EPS of $1.38-$1.46 and reaffirmed 2026 comparable sales growth of 6.5%-7.5% with raised EPS guidance of $5.45-$5.60, while key businesses such as Electrophysiology, Core Lab Diagnostics, Cancer Diagnostics, and Nutrition are set to drive a second-half acceleration. With roughly 60% of sales generated outside the United States, Abbott also benefits from broad global exposure, improving cash generation, and a deep product cycle that includes Libre, MitraClip, Alinity, Volt 2.0, and TactiFlex Duo.

Abbott Laboratories is facing a negative outlook because its electrophysiology momentum appears less robust than hoped, with Volt only entering full U.S. launch mode in mid-August and BSX’s cyber incident too brief to meaningfully boost share gains. Softness in the LAAC market also looks broader than company-specific, prompting lower 3Q/4Q EP growth estimates to +18.0%/+22.5% from +19.8%/+24.4%, while Amulet growth assumptions were cut to reflect weaker demand. Although 2026 comparable CC sales growth guidance of 6.5-7.5% and neutral FX support the long-term case, the stock’s execution risk remains elevated given pricing pressure in Nutrition and Medical Devices, regulatory timing uncertainty, and demand forecasting challenges across emerging markets.